1Oesterling JE, Martin SK, Bergstralh EJ, et al. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer[J]. JAMA, 1993, 269(1):57-60.
2Wymenga LF, Boomsma JH, Groenier K, et al. Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase[J]. BJU Int, 2001, 88(3):226-230.
3Chybowski FM, Keller JJ, Bergstralh EJ, et al. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer:prostate specific antigen in superior to all other clinical parameters[J]. J Urol, 1991, 145(2):313-318.
4Lorente JA, Valenzuela H, Morote J, et al. Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate[J]. Eur J Nucl Med, 1999, 26(6):625-632.
5Stokkel MP, Zwinderman AH, Zwartendijk J, et al. The value of pretreatment clinical and biochemical parameters in staging and prognostic stratification of patients with newly diagnosed prostate carcinoma[J]. Int J Biol Markers, 1998, 13(2):70-76.
6Ballentine Carter H, Partin AW. Diagnosis and staging of prostate cancer. In: Walsh PC, Retic AB, Vaughan ED Jr, et al. Campbell's Urology[M].Vol 3. 7th ed. Philadelphia: WB Saunders,1998.2530-2531.
